These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 32823229)

  • 1. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
    Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
    Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy.
    Wiedower JA; Forbes SP; Tsai LJ; Liao J; Raez LE
    J Manag Care Spec Pharm; 2024 Jul; 30(7):660-671. PubMed ID: 38950156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
    J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Clinical Outcomes after Genomic Profiling of Circulating Tumor DNA in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.
    Olsen S; Liao J; Hayashi H
    Curr Oncol; 2022 Jul; 29(7):4811-4826. PubMed ID: 35877242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.
    Remon J; Swalduz A; Planchard D; Ortiz-Cuaran S; Mezquita L; Lacroix L; Jovelet C; Rouleau E; Leonce C; De Kievit F; Morris C; Jones G; Mercier K; Howarth K; Green E; Pérol M; Saintigny P; Besse B
    PLoS One; 2020; 15(6):e0234302. PubMed ID: 32525942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
    Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
    JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
    Chen H; Wang A; Wang J; He Z; Mao Y; Liu L
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1867-1876. PubMed ID: 32221744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
    Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
    JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
    Reckamp KL; Patil T; Kirtane K; Rich TA; Espenschied CR; Weipert CM; Raymond VM; Santana-Davila R; Doebele RC; Baik CS
    Clin Lung Cancer; 2020 Nov; 21(6):545-552.e1. PubMed ID: 32665165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
    Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
    Antonarakis ES; Tierno M; Fisher V; Tukachinsky H; Alexander S; Hamdani O; Hiemenz MC; Huang RSP; Oxnard GR; Graf RP
    Prostate; 2022 May; 82(7):867-875. PubMed ID: 35286728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
    Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB
    Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.